 |
 |
Oxford Biomedica says Prosavin pre-clincal results encouraging LONDON (AFX) - Oxford Biomedica PLC said it was encouraged by new pre-clinical efficacy results on ProSavin, its Parkinson's treatment, and added that it plans to start a European Phase I/II trial of ProSavin in patients with late-stage Parkinson's disease in 2007. The gene therapy company added that a Phase III trial could start in 2009 and that talks with relevant regulatory agencies are ongoing. The new results showed ProSavin outperformed the standard treatment for Parkinson's disease, L-DOPA, in terms of efficacy, without inducing any of the movement disorders that occur following prolonged treatment with L-DOPA. Long-term data showed that ProSavin's therapeutic benefit was maintained for at least 15 months, the most recent time point, without any loss of effect, the company said. 'These new results substantially strengthen the already impressive pre-clinical data set for ProSavin and confirm its potential as a treatment for Parkinson's disease, particularly when other therapies fail,' said Oxford BioMedica's chief executive Alan Kingsman. 'Its duration of action and lack of side effects are particularly promising,' he added. more on Prosavin on: http://www.oxfordbiomedica.co.uk/prosavin.htm Maryse ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn